Fax: (646) 888-4081
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
Article first published online: 19 MAY 2011
DOI: 10.1002/cncr.26191
Copyright © 2011 American Cancer Society
Additional Information
How to Cite
Stadler, Z. K., Salo-Mullen, E., Patil, S. M., Pietanza, M. C., Vijai, J., Saloustros, E., Hansen, N. A. L., Kauff, N. D., Kurtz, R. C., Kelsen, D. P., Offit, K. and Robson, M. E. (2012), Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer, 118: 493–499. doi: 10.1002/cncr.26191
- †
Fax: (646) 888-4081
Publication History
- Issue published online: 5 JAN 2012
- Article first published online: 19 MAY 2011
- Manuscript Accepted: 24 MAR 2011
- Manuscript Revised: 16 MAR 2011
- Manuscript Received: 10 JAN 2011
REFERENCES
- 1, . BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer. 2004; 4: 665-676.
- 2, , ; New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003; 302: 643-646.
- 3, , , et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997; 336: 1401-1408.
- 4, . Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med. 2007; 357: 154-162.
- 5, , , et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002; 346: 1609-1615.
- 6, , , et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998; 62: 676-689.
- 7, , , et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003; 72: 1117-1130.
- 8[no authors listed]. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer. 2000; 83: 1301-1308.
- 9, , , et al. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res. 2002; 8: 3776-3781.
- 10, , , et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res. 2004; 10: 2029-2034.
- 11, , , et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005; 42: 711-719.
- 12, ; Breast Cancer Linkage Consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002; 94: 1358-1365.
- 13, , , , , . Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002; 94: 1365-1372.
- 14[no authors listed]. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J Natl Cancer Inst. 1999; 91: 1310-1316.
- 15, , , et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 2002; 62: 3789-3793.
- 16, , , et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst. 2003; 95: 214-221.
- 17, , , et al. The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16: 342-346.
- 18, , , et al. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009; 8: 131-135.
- 19, , , et al. The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nat Genet. 1995; 11: 198-200.
- 20, , , et al. The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%. Nat Genet. 1996; 14: 188-190.
- 21, , , , . The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999; 64: 963-970.
- 22, , , et al. Incidence of non-founder BRCA1 and BRCA2 mutations in high risk Ashkenazi breast and ovarian cancer families. J Med Genet. 2002; 39: 611-614.
- 23. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer. Genet Test. 2008; 12: 267-271.
- 24, , , et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol. 2009; 27: 433-438.
- 25, , , et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 1999; 154: 1835-1840.
- 26, , , et al. Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med. 1995; 333: 970-974.
- 27, , , et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996; 14: 141-145.
- 28, , , et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324: 217.
- 29, , , et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998; 16: 2417-2425.
- 30, , , et al. Germline BRCA1 185delAG mutations in Jewish women with breast cancer. Lancet. 1996; 347: 1643-1645.
- 31, , , et al. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer. Nat Genet. 1996; 13: 126-128.
- 32, , , et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002; 20: 1480-1490.
- 33, , , et al. Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006; 24: 354-360.
- 34, . Role of BRCA1 and BRCA2 mutations in pancreatic cancer. Gut. 2007; 56: 601-605.
- 35, , , et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010; 28: 387-391.
- 36, , , et al. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. Cancer Genet Cytogenet. 2005; 158: 119-125.
- 37, , , et al. Germline PALB2 mutation analysis in breast-pancreas cancer families [published online ahead of print March 17, 2011]. J Med Genet.
- 38, , , et al. PALB2 mutations in familial breast and pancreatic cancer [published online ahead of print March 2, 2011]. Fam Cancer.
- 39, , , et al. A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet. 2004; 41: 474-480.
- 40, , , . Update on the Manchester Scoring System for BRCA1 and BRCA2 testing. J Med Genet. 2005; 42: e39.
- 41, , , et al. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study. Fam Cancer. 2010; 9: 495-502.
- 42, , , . Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet. 2008; 9: 116.